Advanced search
Start date
Betweenand

Ana Marisa Chudzinski-Tavassi

CV Lattes ORCID


Secretaria da Saúde (São Paulo - Estado). Instituto Butantan  (Institutional affiliation for the last research proposal)
Birthplace: Brazil

Graduated in Pharmacy and Biochemistry from the Federal University of Paraná, UFPR. Master's and Doctorate in Sciences from the Federal University of São Paulo - UNIFESP (Molecular Biology program). Doctorate from the Pasteur Institute and INSERM (France). Post-doctorate at the National Academy of Medicine of Buenos Aires (ANMBs) - Argentina. She is a PqC-VI scientific researcher at Instituto Butantan where she acts as: Director of the Center for Development and Innovation at Instituto Butantan, Director of CENTD: Center of Excellence in New Target Discovery-FAPESP / GSK / IBu. She is a Productivity Researcher at CNPq and Associate Researcher at CeTICS-FAPESP. She is an accredited professor in the Postgraduate courses: Molecular Biology at UNIFESP, Interunits in Biotechnology at USP and Postgraduate Studies in Toxinology at Instituto Butantan. She acts as a Titular Member of the Municipal Council of Science and Technology and Innovation of the City of São Paulo and is a member of the Brazilian Network of Pharmaceutical Innovation. She serves as an Ad Hoc reviewer for several scientific journals and Funding Agencies. She coordinates projects aimed at public-private interaction, with support from various development agencies. Experience in Biochemistry, with emphasis on the discovery of molecules that act on immunoinflammatory diseases, cell survival, hemostasis and tissue remodeling. She coordinates projects for the discovery and validation of molecular targets in different cell models. Coordinates projects for the implementation of infrastructure for the development of new drugs, such as laboratories with different levels of biosafety, multipurpose laboratories, specialized platforms for the discovery and validation of molecular targets and biorepositories. She works in training in entrepreneurship and innovation through open courses and disciplines in undergraduate and graduate programs. (Source: Lattes Curriculum)

Articles published in Pesquisa FAPESP Magazine about the researcher:
A place in the sun 
Antitumor protein 
Una proteína antitumoral 
News published in Agência FAPESP Newsletter about the researcher
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)
Research grants
Scholarships in Brazil
Scholarships abroad
FAPESP support in numbers * Updated November 26, 2022
Total / Available in English
Most frequent collaborators in research granted by FAPESP
Contact researcher

Use this Research Supported by FAPESP (BV/FAPESP) channel only to send messages referring to FAPESP-funded scientific projects.


 

 

 

 

Keywords used by the researcher
Videos related to Research Grants and Scholarships

Animal venoms as tools for the discovery of new molecular targets: Strategies developed by CENTD

Published by Agência FAPESP - February 12, 2019. The CENTD is a research center focused on the discovery of molecular targets and signaling pathways, implemented at the Butantan Institute, in São Paulo, Brazil, as a result of a typical triple helix collaborative partnership between FAPESP, GlaxoSmithKline (GSK) and Butantan Institute. In it, first-class science is being conducted employing the most modern molecular and cellular biology techniques, including phenotypic multi-parametric assays, interatomic, proteomic, transcriptomic analysis and bioinformatics. The CENTD aims to identify and validate new molecular targets related to immuno-inflammatory and degenerative diseases, like osteoarthritis and cancer, using venoms, toxins and peptides from the Brazilian biodiversity and from other countries. A Biobank was created for the maintenance and management of the venom collection. Pro and anti-inflammatory cell models, tumor cell cultures and tumor translational models were established with the aim of finding active molecules, targets and signaling pathways to allow for the development of innovative medicines. After identification of a potential new target, subsequent validation utilizes molecular biology methodologies like the CRISPR/Cas9 system for gene knockout and expression activation, knockout animals and in vitro and in vivo tests. To date, 19 whole venoms and 28 peptides have been screened for pro and anti-inflammatory effects in 6 cellular models that have been established and standardized, including osteoclasts, chondrocytes, synoviocytes, THP-1 monocyte/macrophage, adipocytes and neurons-like cells. Isolated fractions with potential anti-inflammatory and/or cytoprotective properties have been selected for further validation. In addition, cytoprotective peptides were tested in cell cultures from 10 patients with osteoarthritis (OA) to better understand the molecular mechanisms involved in disease and to find new molecular targets for OA treatment. Concerning cancer models, in addition to studies on tumor cell cultures, we performed transcriptomic studies on spontaneous melanoma tumors occurring in horses in the Butantan Institute`s Farm. Selected tumors were treated with Amblyomin-X, a recombinant Kunitz-type inhibitor derived from a cDNA library from the Amblyomma sculptun tick salivary glands. Amblyomin-X was previously described as a proteasome inhibitor inducing selective cell death in several tumor cells. This molecule promotes endoplasmic reticulum (ER) stress, mitochondrial dysfunction, cytochrome-c release, poly(ADP-ribose) polymerase (PARP) cleavage and activation of caspases in several tumor cell types. Results derived from the transcriptomic analysis of the horse tumor translational model indicate that this molecule triggers immunogenic cell death (ICD) by triggering key molecular pathways. As a general conclusion, the collaborative partnership established in the CENTD could be an effective model for the development of high impact SCIENCE in concert with novel drug discovery. Ana Marisa Chudzinski-Tavassi | FAPESP Week London.
Patent applications

PROCESSO DE PURIFICAÇÃO DE PROTEÍNAS SOLÚVEIS DAS CERDAS DA L. OBLÍQUA COM ATIVIDADE ATIVADORA DE PROTROMBINA; PROCESSO PARA DETERMINAÇÃO PARCIAL DA SEQUÊNCIA DE AMINOÁCIDOS DO ATIVADOR DE PROTROMBINA; PROCESSO DE DETERMINAÇÃO DA ATIVIDADE ATIVADORA DE PROTROMBINA DA FRAÇÃO II, SEQUÊNCIA N-TERMINAL E SEQUÊNCIA DE FRAGMENTOS INTERNOS DA FRAÇÃO ATIVADORA DE PROTROMBINA, ATIVADOR DE PROTROMBINA E USO DO ATIVADOR DE PROTROMBINA PI0200269-8 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Cleyson Valença Reis - January 2002, 31

PURIFICATION AND CHARACTERIZATION OF A PROTHROMBIN ACTIVATOR FROM THE BRISTLED OF LONOMIA OBLIQUA CA2471410 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Chudzinski-Tavassi; Cleyson Reis - January 2003, 29

PURIFICATION AND CHARACTERIZATION OF A PROTHROMBIN ACTIVATOR FROM THE BRISTLED OF LONOMIA OBLIQUA EP20030706143 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Chudzinski-Tavassi; Cleyson Reis - January 2003, 29

PURIFICATION AND CHARACTERIZATION OF A PROTHROMBIN ACTIVATOR FROM THE BRISTLED OF LONOMIA OBLIQUA PCT/BR2003/000012 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Chudzinski-Tavassi; Cleyson Reis - January 2003, 29

PURIFICATION AND CHARACTERIZATION OF A PROTHROMBIN ACTIVATOR FROM THE BRISTLED OF LONOMIA OBLIQUA US10/501,238 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Chudzinski-Tavassi; Cleyson Reis - January 2003, 29

PROCESSO DE OBTENÇÃO DE PROTEASE ATIVADORA DE PROTROMBINA RECOMBINATE (LOPAP) NA FORMA MONOMÉRICA; PROTEASE ATIVADORA DE PROTROMBINA RECOMBINATE (LOPAP), SEQÜÊNCIA DE AMINOÁCIDOS DA PROTEÍNA RECOMBINANTE ASSIM OBTIDA E USO COMO AGENTE DESFIBRINOGENANTE E KIT DIAGNÓSTICO PARA DESPROTROMBINEMIAS PI0403882-7 - Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Cleyson Valença Reis; Paulo Lee Ho; Celso Raul Romero Ramos ; Sandra Helena Poliselli Farsky; Márcio Fritzen - August 2004, 24

PROCESSO DE OBTENÇÃO DE UM INIBIDOR DE PROTEASES DO TIPO KUNITZ A PARTIR DE UMA BIBLIOTECA DE cDNA DE GLÂNDULAS SALIVARES DO CARRAPATO AMBLYOMMA CAJENNENSE: SEQUÊNCIA DE OLIGONUCLEOTÍDEOS DO CLONE, E SEQUÊNCIA DE AMINOÁCIDOS DA PROTEÍNA RECOMBINANTE, PROTEÍNA RECOMBINANTE; PROCESSO PARA DETERMINAÇÃO DA ATIVIDADE INIBITÓRIA SOBRE O FATOR X ATIVADO, PROCESSO PARA DETERMINAÇÃO DA ATIVIDADE ANTICOAGULANTE EM PLASMA, PROCESSO PARA DETERMINAÇÃO DA ATIVIDADE APOPTÓTICA EM LINHAGENS DE CÉLULAS TUMORAIS HUMANAS E MURINAS, PROCESSO DE DETERMINAÇÃO DE ATIVIDADE ANTI-METASTÁTICA EM TUMOR DE MELANOMA, PROCESSO DE DETERMINAÇÃO DA ATIVIDADE ANTI-CÂNCER, IN VITRO E IN VIVO, USO DO RECOMBINANTE EM DIFERENTES MECANISMOS HOMEOSTÁTICOS (COAGULAÇÃO E RESPOSTA IMUNOLÓGICA), ANTI-PROLIFERATIVOS, ANTI-APOPTÓTICOS E ANTI-ANGIOGÊNICOS PI0406057-1 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - September 2004, 15

PROCESS FOR OBTAINING RECOMBINANT PROTHROMBIN ACTIVATING PROTEASE (RLOPAP) IN MONOMERIC FORM; THE RECOMBINANT PROTHROMBIN ACTIVATING PROTEASE (RLOPAP) AS WELL AS ITS AMINO ACID SEQUENCE; THE USE OF THIS PROTEASE AS A DEFIBRINOGENASE US11/574,213 - Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Cleyson Valenca Reis; Paulo Lee Ho; Celso Romero Ramos - August 2005, 24

PROCESS FOR OBTAINING RECOMBINANT PROTHROMBIN ACTIVATING PROTEASE (RLOPAP) IN MONOMERIC FORM; THE RECOMBINANT PROTHROMBIN ACTIVATING PROTEASE (RLOPAP) AS WELL AS ITS AMINO ACID SEQUENCE; THE USE OF THIS PROTEASE AS A DEFIBRINOGENASE AGENT AND THE DIAGNOSIS KIT FOR DYSPROTHROMBINEMIAS PCT/BR2005/000171 - Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Cleyson Valença Reis; Paulo Lee Ho; Celso Romero Ramos - August 2005, 24

COMPOSIÇÕES FARMACÊUTICAS BASEADAS EM LOPAP E USOS DAS DITAS COMPOSIÇÕES PI0504199-6 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Márcio Falci; Durvanei Augusto Maria; Cleyson Valença Reis - September 2005, 08

INHIBIDOR RECOMBINANTE DE TIPO KUNITZ ES2410160 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - September 2005, 15

KUNITZ-TYPE RECOMBINANT INHIBITOR EP20050782904 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - September 2005, 15

KUNITZ-TYPE RECOMBINANT INHIBITOR PCT/BR2005/000185 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - September 2005, 15

LOPAP-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CA2577915 - Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Cleyson Valença Reis; Paulo Lee Ho; Celso Raul Romero Ramos ; Sandra Helena Poliselli Farsky; Márcio Fritzen - September 2006, 08

LOPAP-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EP20050774298 - Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Cleyson Valença Reis; Paulo Lee Ho; Celso Raul Romero Ramos ; Sandra Helena Poliselli Farsky; Márcio Fritzen - September 2006, 08

LOPAP-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF PCT/BR2006/000180 - Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Cleyson Valença Reis; Paulo Lee Ho; Celso Raul Romero Ramos ; Sandra Helena Poliselli Farsky; Márcio Fritzen - September 2006, 08

METHODS FOR GROWING TISSUE WITH LOPAP-BASED PHARMACEUTICAL COMPOSITIONS US12/066,192 - Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Cleyson Valença Reis; Paulo Lee Ho; Celso Raul Romero Ramos ; Sandra Helena Poliselli Farsky; Márcio Fritzen - September 2006, 08

METHODS FOR GROWING TISSUE WITH LOPAP-BASED PHARMACEUTICAL COMPOSITIONS CA2621482 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Márcio Falci; Durvanei Augusto Maria; Cleyson Valença Reis - September 2006, 08

METHODS FOR GROWING TISSUE WITH LOPAP-BASED PHARMACEUTICAL COMPOSITIONS CN200680040955 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Márcio Falci; Durvanei Augusto Maria; Cleyson Valença Reis - September 2006, 08

METHODS FOR GROWING TISSUE WITH LOPAP-BASED PHARMACEUTICAL COMPOSITIONS EP20060775034 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Márcio Falci; Durvanei Augusto Maria; Cleyson Valença Reis - September 2006, 08

KUNITZ-TYPE RECOMBINANT INHIBITOR CA2581001 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - March 2008, 14

KUNITZ-TYPE RECOMBINANT INHIBITOR CA2680759 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - March 2008, 14

KUNITZ-TYPE RECOMBINANT INHIBITOR CN200580038992 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - March 2008, 14

KUNITZ-TYPE RECOMBINANT INHIBITOR EP20080733487 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - March 2008, 14

KUNITZ-TYPE RECOMBINANT INHIBITOR PCT/BR2008/000078 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - March 2008, 14

KUNITZ-TYPE RECOMBINANT INHIBITOR US11/724,557 - Ana Marisa Chudzinski-Tavassi; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); União Química Farmacêutica Nacional S.A.. Ana Marisa Chudzinski-Tavassi; Durvanei Augusto Maria; Isabel de Fátima Correia Batista; Paulo Lee Ho - March 2008, 14

PEPTÍDEO ISOLADO E SEU USO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA REDUZIR MORTE CELULAR E DEGENERAÇÃO TECIDUAL, MÉTODO PARA REGENERAÇÃO TECIDUAL EM UM ALVO E MÉTODO PARA CURAR FERIMENTO PI0907469-4 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi - January 2009, 22

PEPTIDES, COMPOSITIONS, AND USES THEREOF CA2712807 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Janaina de Souza Ventura; Linda Christian Carrijo Carvalho - January 2009, 22

PEPTIDES, COMPOSITIONS, AND USES THEREOF CN200980108018 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Janaina de Souza Ventura; Linda Christian Carrijo Carvalho - January 2009, 22

PEPTIDES, COMPOSITIONS, AND USES THEREOF EP20090704223 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Janaina de Souza Ventura; Linda Christian Carrijo Carvalho - January 2009, 22

PEPTIDES, COMPOSITIONS, AND USES THEREOF IL207174 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Janaina de Souza Ventura; Linda Christian Carrijo Carvalho - January 2009, 22

PEPTIDES, COMPOSITIONS, AND USES THEREOF JP2011510060 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Janaina de Souza Ventura; Linda Christian Carrijo Carvalho - January 2009, 22

PEPTIDES, COMPOSITIONS, AND USES THEREOF PCT/IB2009/050237 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Janaina de Souza Ventura; Linda Christian Carrijo Carvalho - January 2009, 22

PEPTIDES, COMPOSITIONS, AND USES THEREOF US12/863,922 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Janaina de Souza Ventura; Linda Christian Carrijo Carvalho - January 2009, 22

PÉPTIDOS, COMPOSICIONES, Y SUS USOS ES2559195 - Ana Marisa Chudzinski-Tavassi; Biolab Sanus Farmacêutica Ltda; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Ana Marisa Chudzinski-Tavassi; Janaina de Souza Ventura; Linda Christian Carrijo Carvalho - January 2009, 22

Please report errors in researcher information by writing to: cdi@fapesp.br.
X

Report errors in this page


Error details: